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ABSTRACT
Aim: We examined the effects on gastrointestinal (GI) tolerance of a novel infant formula
that combined specific fermented formula (FERM) with short-chain galacto-
oligosaccharides and long-chain fructo-oligosaccharides (scGOS/lcFOS), with a 9:1 ratio
and concentration of 0.8 g/100 mL.
Methods: This prospective, double-blind, randomised, controlled trial comprised 432
healthy, term infants aged 0–28 days whose parents decided to not start, or discontinued,
breastfeeding. Infant formula with scGOS/lcFOS+50%FERM, scGOS/lcFOS+15%FERM,
50%FERM and scGOS/lcFOS were tested. Parents completed standardised seven-day
diaries on GI symptoms, crying, sleeping and stool characteristics each month until the
infants were 17 weeks.
Results: All the formulas were well tolerated. At four weeks, the overall incidence of
infantile colic was significantly lower (8%) with scGOS/lcFOS+50%FERM than scGOS/
lcFOS (20%, p = 0.034) or 50%FERM (20%, p = 0.036). Longitudinal modelling showed
that scGOS/lcFOS+50%FERM-fed infants also displayed a persistently lower daily crying
duration and showed a consistent stool-softening effect than infants who received formula
without scGOS/lcFOS.
Conclusion: The combination of fermented formula with scGOS/lcFOS was well tolerated
and showed a lower overall crying time, a lower incidence of infantile colic and a stool-
softening effect in healthy term infants. These findings suggest for the first time that a
specific infant formula has a preventive effect on infantile colic in formula-fed infants.
INTRODUCTION
Exclusive breastfeeding is the preferred feeding method for
all newborn infants and provides complete nutrition to
support growth and development in early life (1). A wide
range of short-term and long-term neuronal, immune,
metabolic and gut health benefits have been reported for
breastfed infants (2–4). Gut health in early life has been
Abbreviations
FERM, A specific fermented formula called Lactofidus; FGID,
Functional gastrointestinal disorders (FGIDs); GI, Gastrointesti-
nal; scGOS/lcFOS, Short-chain galacto-oligosaccharides and
long-chain fructo-oligosaccharides.
Key notes
 We examined the effects on gastrointestinal tolerance
of a novel infant formula that combined specific
fermented formula with short-chain galacto-oligo-
saccharides and long-chain fructo-oligosaccharides
(scGOS/lcFOS).
 The combination of scGOS/lcFOS and 50% fermented
formula was particularly well tolerated, with 60% less
infantile colic at four weeks of age and lower daily
crying duration.
 The findings demonstrate the possible preventive
effects of infant formula on infantile colic for the
first time.
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shown, in this context, to have an impact on fundamental
aspects of psychosocial, physical and mental well-being in
later life. As it is not always possible to provide an infant
with human milk, any substitutes should provide functional
benefits that are as close as possible to those of human milk.
This study presents the results of a randomised, con-
trolled trial of a novel infant formula on gastrointestinal
(GI) tolerance, based on the secondary outcome parameters
of growth, safety and GI tolerance. The primary outcome
parameters of growth and safety have previously been
described (5). This novel infant formula combines two well-
defined and established concepts that have each been
demonstrated to have beneficial effects on gut health: a
specific fermented formula (FERM) called Lactofidus
(Danone Nutricia, Steenvoorde, France) and a specific
mixture of prebiotic oligosaccharides, namely short-chain
galacto-oligosaccharides and long-chain fructo-oligosac-
charides (scGOS/lcFOS), with a ratio of 9:1 and a concen-
tration of 0.8 g/100 mL (6,7).
The FERM has previously been reported to alleviate
symptoms of GI discomfort in infants that consumed it in a
thickened formula (6). Fermentation is a natural process
that was initially developed for food preservation and later
became a controlled means to equip foods with particular
properties, such as specific tastes, textures and health
benefits (8). FERM is distinct from infant formulas that
are, for example, supplemented with prebiotics or probi-
otics or contain hydrolysed protein (6,9–11).
The novel scGOS/lcFOS infant formula, with a ratio of 9:1
andaconcentrationof0.8 gper100 mL,wasdevelopedbased
on scientific insights fromhumanmilk research (12). Formula
supplementation with scGOS/lcFOS has been demonstrated
to modulate early microbiota development, gut ecophysiol-
ogy, stool consistency and immune functions in ways that are
close to that found in breastfed infants (7,13–15).
We hypothesised that the combination of the specific
fermented formula with the specific prebiotic mixture,
scGOS/lcFOS, could have a complementary and beneficial
effect on gut health and function, for example by preventing
functional GI disorders and related signs and symptoms in
infants. Here, we present the secondary outcomes, namely
GI tolerance parameters and crying time, of the novel
infant formula concept, using a prospective, double-blind,
randomised, controlled trial design.
METHODS
Trial design and registration
This trial was a prospective, double-blind, randomised,
four-arm parallel group, controlled, multicentre equiva-
lence trial on growth, safety and GI tolerance. It included
hospitals and private practices in France, Belgium and
Ireland. Each of the 432 infants was randomly assigned to
one of the four parallel groups, which contained equal
numbers. The study was registered with the Dutch Trial
Register on September 17, 2010 (registration number
NTR2521), and the approval of the relevant ethics com-
mittees in the participating countries was obtained before
the start of the study. Baseline measurements were taken on
study inclusion, and parents received the assigned infant
formula with written preparation instructions and were
advised to feed infants on demand.
Study products
The composition of the trial products has previously been
described (5). In brief, all study products were iso-caloric,
powdered, cows’ milk-based infant formulas for bottle-fed
babies aged0–6 months andeach100 mLcontained about 66
kilocalories of energy, 1.35 g of protein, 8.2–8.4 g of carbohy-
drate, 3.0–3.1 g of lipids, plus vitamins and minerals, accord-
ing to European Commission Directive 2006/141/EC.
The infant formulas only varied in the amount of formula
produced by a specific fermentation process, as well as the
presence of scGOS/lcFOS, with a ratio of 9:1 and concen-
tration of 0.8 g/100 mL. The formulas that were tested
contained: (i) just scGOS/lcFOS, (ii) just 50%FERM,
(iii) scGOS/lcFOS+15%FERM and (iv) scGOS/lcFOS+
50%FERM.
The percentages of FERM related to the ratio of fully
fermented infant formula mixed with nonfermented infant
formula during production: for example, two of the formu-
las consisted of a blend of fermented and nonfermented
formula in a ratio of 15:85 (scGOS/lcFOS+15% FERM),
and 50:50 (scGOS/lcFOS+50% FERM). The only formula
tested in this trial that did not contain scGOS/lcFOS was
50%FERM.
The rationale behind the prebiotic supplementation of a
product with 50% FERM was based on the previously
observed beneficial effects of the separate components on
GI comfort (7,10). The product with a combination of
prebiotics and 15% FERM was included to assess a
potential dose dependency, given the unknown impact the
newly developed formulas would have on safety and
tolerance (5). All the formulas had a similar taste, smell
and colour and were manufactured according to good
manufacturing practices by Nutricia, Steenvoorde, France,
and were provided by Nutricia Research, the Netherlands.
The study products were stored in a secure and limited
access storage area at the sites, where they were protected
from extremes of light, temperature and humidity.
Study conduction
The parents or guardians of infants likely to meet the
eligibility criteria were informed about the study. After
obtaining informed consent at the combined screening and
baseline visit, the eligible infants were randomly assigned to
one of the four study groups. At this first visit, baseline data
were collected and the parents were given one of the four
study products and diaries. Baseline data included their
general experience of the severity of GI symptoms since
birth, stool frequency and consistency and the duration and
number of crying and sleeping episodes.
Further study visits were conducted at four, eight, 13 and
17 weeks after birth (Fig. 1A). Depending on the age at
inclusion, the four-week visit may have been combined
with the screening and baseline visit. Anthropometrical
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measurements were performed at each visit, and adverse
events, the use of medication and nutritional supplements
were documented. Parents were asked to record GI symp-
toms, crying and sleeping, stool characteristics and study
product intake in the diary they were given, for the seven-
day period prior to the study visits. The only possible
exception was the four-week visit, depending on age of
inclusion. Two weeks after the final visit, a follow-up phone
call took place to record adverse events and the use of
medication and nutritional supplements. When we included
this noninterventional follow-up period of two weeks in the
study period, the duration for each infant from randomisa-
tion to the final phone call was 15–19 weeks, depending on
the infant’s age at inclusion.
Study sites, inclusion and exclusion criteria,
and compliance
Infants were recruited by 24 hospitals and private practices
in Belgium (10 sites), Ireland (seven sites) and France
(seven sites). According to the study protocol, infants were
eligible to take part if they were healthy born at a
gestational age of 37–42 weeks and aged 28 days or less
at the time of inclusion. They also needed to have a
birthweight between the 10th and 90th percentile, accord-
ing to locally applicable growth charts, and the latter was
adjusted during the study to a birthweight between 2500
and 4500 g. The written informed consent of a parent or
guardian was also required.
The exclusion criteria were congenital conditions and/or
previous or current illnesses that could interfere with the
study, a known or increased risk of cows’ milk allergy, soy
allergy and/or lactose intolerance, gestational diabetes,
participation in another clinical trial and the investigator’s
uncertainty about the willingness or ability of the parents to
comply with the protocol requirements.
Parents or guardians of infants were instructed, whenever
possible, not to feed the child other infant formulas than the
study product during the study and to complete the diaries
that were provided in the seven-day period prior to the
scheduled study visits. The study product compliance, in
terms of the duration of intake, was assessed.
In order to encourage mothers to continue breastfeeding
as long as possible, the exclusion criterion of breastfeeding
more than once a day was replaced by any breastfeeding.
We decided that only mothers and parents who autono-
mously decided to stop breastfeeding should be informed
about the study and be allowed to participate with their
infant. We also added that parents or guardians should be
aged at least 18 years. The inclusion criterion of a parent’s
or guardian’s written informed consent was adapted by a
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Figure 1 (A) Study visits were conducted at four, eight, 13 and 17 weeks after birth. At four weeks, this visit may have been combined with the screening/baseline visit,
depending on the age at inclusion. (B) Randomisation, dropouts and study completers. From the 432 randomised infants, one infant with hypothyroidism was excluded
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country-specific amendment that it was sufficient for one of
the parents or guardians to sign the consent form.
Outcome measures and data collection
The primary outcome parameter was weight gain in grams
per day from inclusion until 17 weeks of age, and the results
have been previously reported (5). The secondary outcome
parameters were severity of the GI symptoms, namely
constipation, diarrhoea, abdominal distension, flatulence,
regurgitation, vomiting, diaper dermatitis and arching of the
back, the frequency and duration of crying and sleeping, the
incidence of infantile colic and the frequency and consis-
tency of stool characteristics.
The primary objective of the study was to test for
equivalence of weight gain per day between the control
and test products. The power calculation that was needed
has been presented elsewhere (5). No separate sample size
calculation was performed in respect to the secondary
outcomes.
An interim analysis was performed after 106 infants,
approximately 40%, of the initially calculated sample size of
280 infants, completed the intervention period to evaluate
the assumptions for the sample size calculation and to
analyse the safety of the products tested. An independent
data monitoring committee evaluated the interim results.
The randomisation sequence was computer generated.
Product stratification was applied for the centre and sex of
the infant. All details of the randomisation, including block
size, were unknown to the investigator, site staff and study
staff from Nutricia Research, except for the clinical studies
supplies manager of Nutricia Research.
After the eligibility of an infant was assessed and
informed consent was obtained, the infant was included
in the study. Based on the order in which infants entered
the study, and the stratification factor, they were assigned a
randomisation number and the correspondingly numbered,
opaque, sealed randomisation envelope was opened, reveal-
ing the code of the study product – A, B, C or D – that was
assigned to the randomisation number beforehand.
Data were collected from the study sites, while respecting
the blinding and anonymity of all the infants. All data were
entered by double data entry (blind verification) into the
clinical trial database, which was ClinTrial, version 4.6
(Oracle USA, Inc., Redwood City, CA 94065, USA). Data
remained blinded until the data review meeting was
completed, the statistical analysis plan was validated and
the database was locked.
Baseline data were based on the parent’s recall. After this,
the parents were asked to complete seven-day diaries with
daily entries during the week before the next study visit,
which were scheduled when the infants were four, eight, 13
and 17 weeks. They were asked to return the diaries at the
next visit. The GI symptoms that were evaluated were
constipation, diarrhoea, abdominal distension, flatulence,
regurgitation, vomiting, diaper dermatitis and arching of the
back. Parents were asked to score these from 0 to 3 on a
daily basis, when these were absent, mild, moderate or
severe, respectively.
The periods when the infant cried or slept were also
recorded. Based on the parents’ entries, the total duration of
crying and sleeping per day was transferred into the case
report form, as well as the number of crying and sleeping
episodes per day.
In addition, parents received instruction on how to assess
and record the consistency of each stool that was passed
on a five-point scale, as watery (score = 1), soft, pudding
like (=2), soft, formed (=3), dry formed (=4) or dry, hard
pellets (=5).
Statistical analysis
Of the 432 randomised infants, one infant with hypothy-
roidism was excluded from the intention to treat popula-
tion, as this infant was not considered as healthy as first
thought and had been erroneously randomised (Fig. 1B).
The 431 infants in the study population were defined as the
primary set for the analysis of the secondary tolerance
parameters: GI symptoms, crying and sleeping, stool char-
acteristics. Only diaries with three or more days of
completed entries for each parameter that was analysed
were considered for analysis.
From the diary data, namely the daily recorded severity
score on GI symptoms, a mean value per symptom was
calculated for each infant and age category, at baseline,
four, eight, 13 and 17 weeks. The baseline data were based
on parental recall. The same parameters and process were
used to determine mean values on the frequency and
duration of crying and sleeping. Furthermore, the informa-
tion recorded in the diaries on crying duration was used to
calculate the incidence of infantile colic, which was
considered to be present, if the infant cried for at least
three hours per day for at least three days, based on the
adapted ROME III criteria (16). The parent’s recall of the
mean duration of crying per day was only collected at
baseline, but we did not ask how many times the crying
exceeded three hours each week. Therefore, the incidence
of colic was not calculated at baseline.
A mean value was calculated per infant and age category
from the parental recall at baseline and the diary data on
stool consistency score and frequency.
Two-sample t-tests were used for the continuous data –
mean severity scores for GI symptoms, crying and sleeping
duration, number of crying and sleeping episodes, mean
stool consistency and mean stool frequency, and the
Wilcoxon rank-sum tests were used if there was violation
of the normality assumption and/or the presence of outliers.
The incidence of GI symptoms and infantile colic was
analysed by the chi-square test, or in case of sparse cell
counts, by Fisher’s exact test. Statistical tests were per-
formed at each week of age: at baseline, except for infantile
colic, and at four, eight, 13 and 17 weeks.
The first test product – scGOS/lcFOS+50%FERM – was
compared with both control products 50%FERM and
scGOS/lcFOS, and the second test product – scGOS/
lcFOS+15%FERM – was only compared with one control
product, scGOS/lcFOS. However, using the second test
product with 15%FERM also provided insight into the
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effect of the level of fermentation on GI tolerance against
the first test product, scGOS/lcFOS + 50%FERM.
Daily crying time was analysed post hoc using a
longitudinal model. For this, the total duration of crying
per diary day was calculated for each infant. The time, in
terms of the number of days each infant was on the study
product, was standardised prior to its use as the indepen-
dent variable in the regression analysis. It was defined as
ti = (days on study product – the sample mean number of
days on study product)/standard deviation of days on
study product.
The association between infantile colic with GI symp-
toms was analysed post hoc by combining all the study
product arms to investigate the incidence of a GI symptom
by the incidence of colic at the ages of four and eight weeks.
The incidence of a GI symptom was derived from the
severity scores and calculated using the chi-square test for
each infant and age category. A symptom was considered to
be present, and more severe than just mild, when the
severity score of an infant was more than one. Fisher’s exact
test was used for sparse cell counts. Furthermore, odds
ratios and corresponding 95% confidence intervals were
calculated. The numbers of infants with infantile colic was
not equally distributed across the study arms due to the
intervention, for example at four weeks, it affected 20% of
infants in the 50%FERM study arm and scGOS/lcFOS arm,
versus 8% of the infants in the scGOS/lcFOS+50%FERM
study arm. Therefore, it was not statistically sound to
compare the association between functional symptoms with
infantile colic for each intervention group due to different
formulas and treatment bias and differences in incidence.
No correction for covariates and no correction for
multiple testing were applied.
RESULTS
Participant flow, demographics, other infant
characteristics
The demographics and characteristics of the intention to
treat population when they entered the study have been
previously described (5). In brief, 276 of the 432 ran-
domised infants completed the study and the reasons for the
study withdrawals are detailed for each study arm (Fig. 1B).
There were no statistically significant differences in the
number of infants who terminated the study early, the
reasons for withdrawal, the overall study compliance and
the study product intake between the study arms (data not
shown). The primary objective of the trial on growth and
safety has previously been reported (5). In brief, all infant
formulas resulted in normal growth in healthy infants and
there were no differences between formulas in the number
or severity of adverse events (5).
Interim analysis
During the interim analysis, the independent data monitor-
ing committee concluded that there was no need to increase
the sample size above the number initially calculated and
that there were no concerns regarding safety.
Gastrointestinal symptom scores
Over the entire intervention period, and in all the four study
arms, the median symptom scores for constipation, diar-
rhoea, abdominal distension, vomiting, diaper dermatitis
and arching of the back were below one, which indicated
that they were mild. The highest mean GI symptom scores
that were reported by the parents were flatulence and
regurgitation. The only statistically significant difference for
these two symptoms was found for flatulence at eight weeks
of age, where the Wilcoxon rank-sum test showed that
scGOS/lcFOS+50%FERM (median 1.2) displayed a higher
average symptom score than scGOS/lcFOS+15%FERM
(median 1.0, p = 0.017,) and scGOS/lcFOS (median 1.0,
p = 0.01). There were no statistically significant differences
found for any other symptom with a symptom score
above one.
Stool frequency and consistency
There were no statistically significant differences in the
average stool frequency during the study period between
the study arms according to the Wilcoxon rank-sum test
(Fig. 2A). On average, scGOS/lcFOS+50%FERM dis-
played, lower stool consistency scores (p < 0.001) com-
pared to 50%FERM at four, eight, 13 and 17 weeks of age
when using the test (Fig. 2B). In addition, scGOS/
lcFOS+50%FERM (mean 1.94, p = 0.033) and scGOS/
lcFOS (mean 1.95, p = 0.043,) displayed a lower stool
consistency than scGOS/lcFOS+15%FERM at the age of
eight weeks (Fig. 2B).
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Figure 2 Stool parameters. A mean value was calculated per infant and week
from the parental diaries for (A) frequency, (B) consistency (watery = 1, soft,
pudding like = 2, soft, formed = 3, dry formed = 4 or dry, hard pellets = 5).
(*p ≤ 0.05, **p < 0.001; Wilcoxon rank-sum test).
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Crying time and incidence of infantile colic
T-tests for each time point failed to show statistically
significant differences in the duration of crying between the
study arms.
At four weeks of age, the statistical average for the
number of crying episodes per day was significantly lower
with scGOS/lcFOS+50%FERM than 50%FERM (median
2.64 versus 3.38 crying episodes per day, p = 0.030),
according to the Wilcoxon rank-sum test (Fig. 3A).
Across all four study arms, the highest incidence of
infantile colic, based on the adapted Rome III criteria –
16.1% of 292 infants – was found at four weeks of age and
was lower at later time points, namely 10.6% of 284 infants
at eight weeks, 2.2% of 272 infants at 13 weeks and 0.7% of
267 infants at 17 weeks.
At four weeks of age, the chi-square test showed a
statistically significantly lower incidence of infantile colic
with scGOS/lcFOS+50%FERM (8% of 75 infants) than
50%FERM (20% of 70 infants, p = 0.036) and scGOS/
lcFOS (20% of 75 infants, p = 0.034; Fig. 3B). There were
no statistically significant differences at other time points.
During the 17-week infantile formula study period,
scGOS/lcFOS+50%FERM-fed infants persistently dis-
played a significantly lower daily crying duration than
scGOS/lcFOS-fed infants (p = 0.037; Fig. 3C). The statisti-
cal model provided a statistical inference for differences in
profiles covering the entire intervention period. For exam-
ple, after 56 days on the study product, the mean crying
duration for scGOS/lcFOS was 74 minutes and this was
25% lower, at 55 minutes, for scGOS/lcFOS+50%FERM.
There was no statistically significant difference in the
median crying duration at baseline between the four
study arms.
Duration and number of sleeping episodes
There was no indication of a statistically significant differ-
ence in the number of sleeping episodes or sleeping
duration at any time point for any study group comparison
(data not shown).
Results of the post hoc analysis on infantile colic
Irrespectively of the study groups, the GI symptoms that
had the highest incidence rates at four and eight weeks of
age were flatulence (50% and 42.9% of infants, respectively)
and regurgitation (25.7% and 24.3% of infants, respec-
tively). The association between GI symptoms and infantile
colic at four and eight weeks of age is reported in Figure 4.
At 13 and 17 weeks of age, the incidence of infantile colic
was too low for statistical assessment. For example, at four
weeks of age, infants with colic had an approximately
threefold to sixfold higher chance of also having flatulence,
regurgitation, constipation, diarrhoea or vomiting than the
infants without colic (Fig. 4).
DISCUSSION
Gut health in early life is an integrated concept that
includes, and impacts on, the development of the immune,
metabolic and neuronal systems. Due to the complex and
highly dynamic development of the GI system and micro-
biota in early life, healthy term infants can experience a
number of functional gastrointestinal disorders (FGIDs)
and related signs and symptoms early in life, which cannot
be explained by obvious structural or biochemical abnor-
malities (16,17). It has been reported that at least one of two
infants display one or more FGIDs, such as functional
constipation or infantile colic, or related signs and symp-
toms such as hard stools or excessive crying (18,19). Even
though FGIDs are mostly seen as benign in nature, and
usually resolve over time, these may constitute early
traumatic events that cause appreciable distress to infants
and parents, with pending long-term consequences for the
well-being of both (20–27). Considering the high incidence
and impact of early-life FGIDs, their prevention would be
preferable to their treatment, with the implication that
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Figure 3 Crying and infantile colic. (A) mean number of crying episodes per
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the percentage of infants that fulfilled these criteria. (*p ≤ 0.05, crying episodes
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nutritional solutions would be preferable to pharmacolog-
ical interventions. The evidence for the prevention of
FGIDs and related signs and symptoms by nutritional
concepts is limited. This study presents evidence in this
area, based on the results of the secondary outcome
parameters of a four-arm, randomised controlled trial on
growth, safety and GI tolerance of a novel infant formula.
The general strengths of this study include the double-
blind randomised, controlled trial design, the detailed daily
diaries on crying time, for example when compared to
weekly recall, and other GI tolerance parameters. We
concluded that all formulas were well tolerated, based on
the low GI symptom scores from all four study arms over
the entire intervention period. However, it was shown as a
secondary study outcome that the incidence of infantile
colic was influenced by the infant formula composition. An
incidence of infantile colic of 20% in the intervention
groups that received either scGOS/lcFOS or 50%
FERM was in the range of the incidence reported for
population-based studies and reviews (18,19). The formula
containing the combination of scGOS/lcFOS with 50%
FERM displayed a 60% lower incidence of infantile colic at
four weeks of age, compared to those containing either
FERM or scGOS/lcFOS. These results suggest a synergistic
effect of the FERM and scGOS/lcFOS, and the underlying
mode of action may require further investigation.
Given that all the collected data were from healthy term
infants, any effect on infants with infantile colic, namely
20% of the study population (18,19), would be expected to
only have a limited effect on the average crying time of the
total study group. Nonetheless, longitudinal modelling
demonstrated that during the 17-week intervention, there
was a persistently, and significantly, lower daily crying
duration in the scGOS/lcFOS+50%FERM-fed infants than
in the scGOS/lcFOS-fed infants. This suggests that this
formula had an effect during the whole intervention period
and not just around the age of four weeks. Based on the
study design, namely the inclusion of healthy term infants
shortly after birth, the lower incidence of infantile colic and
the lower crying duration in infants fed the combination of
50% FERM and scGOS/lcFOS, we can conclude that this
combination may have had a preventive effect on infantile
colic. To the best of our knowledge, there is surprisingly
little quantitative data available to substantiate the origin of
GI infantile colic. A broad range of nongastrointestinal
conditions, ranging from migraine to the maladaptive
behaviour of infants, have been suspected to be linked to
infantile colic (17). Although the data presented here were
derived from a nutritional intervention study, the overall
picture that emerged was that parental reported functional
GI symptoms were more commonly observed in infants
with infantile colic than those without (Fig. 4). As func-
tional GI symptoms can cause considerable discomfort,
these could be causally linked to crying or an underlying
process that is by itself associated with inconsolable crying.
A potential next step would be to confirm the link of
functional GI symptoms and infantile through, for example,
a prospective observational study.
Hard stools can be commonly observed in infants fed
with a formula without prebiotic oligosaccharides, but are
rarely seen in breastfed infants (15,28). For example, infants
below one year of age have been reported to constitute the
highest rate of constipation-related emergency department
visits in the United States (29). The difference in stool
consistency between breastfed and formula-fed infants has
partly been attributed to human milk oligosaccharides,
which are present in human milk at levels of approximately
10 g/L (7, 30). In this study, infants who consumed the
formula containing scGOS/lcFOS+50%FERM had softer
stools than the infants consuming formula with just 50%
FERM. Whether this effect also has the potential to prevent
constipation needs to be evaluated in future trials.
CONCLUSION
This study investigated the safety and tolerance of a novel
infant formula that combined scGOS/lcFOS with a 9:1 ratio
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and concentration of 0.8 g/100 mL and a specific FERM, in
healthy term infants. Based on the low mean GI symptom
scores that were obtained, all of the study formulas
appeared to be well tolerated. The combination of
scGOS/lcFOS and 50% FERM showed a secondary study
outcome of consistent stool softening when it was com-
pared to the formula without scGOS/lcFOS. It also showed
a significantly lower incidence of infantile colic at four
weeks of age, when compared to formulas that contained
either FERM or scGOS/lcFOS. Interestingly, longitudinal
modelling of daily crying duration over the 17 weeks of the
intervention showed that scGOS/lcFOS+50%FERM-fed
infants also displayed a persistently lower daily crying
duration throughout the study period. Overall, this may
indicate a synergistic effect of the partly fermented formula
combined with scGOS/lcFOS. More studies are needed to
further evaluate this effect.
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